Humalog is named as an intervention in 2 current clinical trials in our Denmark and Canada registers. 1 is recruiting patients now. All registered phases are Not applicable. The sponsor with the most trials is Steno Diabetes Center Copenhagen (1). The most-studied condition is Type 1 Diabetes. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Trial of Three- and Seven-days Insulin Infusions Set
NCT06532461 · ClinicalTrials.gov ↗ · Type 1 Diabetes
|
Not applicable | Recruiting | Steno Diabetes Center Copenhagen | Denmark |
|
Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia
NCT05748990 · ClinicalTrials.gov ↗ · Schizophrenia, Healthy
|
Not applicable | Active, closed | Centre for Addiction and Mental Health | Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Humalog. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
High-dose Insulin Euglycemic Therapy in Non-Toxic Acute Cardiogenic Shock.
2025-523858-13-01 · Cardiovascular Diseases
|
Phase 2 | Authorised | Oslo Universitetssykehus HF | Norway |
| Lead sponsor | Trials |
|---|---|
| Steno Diabetes Center Copenhagen | 1 |
| Centre for Addiction and Mental Health | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Denmark | 1 | 1 |
| Clinical trials in Canada | 1 | 0 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our Denmark and Canada registers name Humalog as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Denmark. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Steno Diabetes Center Copenhagen (1) and Centre for Addiction and Mental Health (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Humalog works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Humalog works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Humalog (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.